Searched for
TENELIGLIPTIN
Good news for diabetes & BP patients: Govt cuts prices of these 30 medicines, relief may reach pharmacies soonThe National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 30 essential drug formulations, including those for diabet...- Glenmark launches triple-drug combo for type 2 diabetesGlenmark Pharmaceuticals has launched a triple-fixed-dose combination drug called Zita for the treatment of Type 2 diabetes. The drug, whic...
- Glenmark Pharmaceuticals rises 5% on launching first 3-drug FDC for type-2 diabetes in India“This FDC has been launched under the brand name Zita®-PioMet,” the company said in a BSE filing. “This offers patients with Type 2 diabete...
- Anti-diabetes drugs and patented antivirals to get cheaper, NLEM notifiedFor the first time, patented drugs like anti-TB bedaquiline and delamanid, anti-HIV Dolutegravir and anti-hepatitis C daclatasvir are also ...
- Glenmark Pharma launches drug for diabetic patients with comorbiditiesThe new drug is well researched and affordable fixed-dose combination, which will significantly improve glycemic control in adult patients,...
- Generics of MSD diabetes pill set to flood market as patent expiresAccording to market research firm AIOCD, at least 50 Indian drug makers are jumping into the fray with around 100 generic versions of the p...
- Government slashes prices of about 39 commonly-used drugsThe drugs brought under price control include teneligliptin-an anti diabetes drug, popular anti TB drugs like Bedaquiline and Delamanid, Iv...
- Glenmark Life IPO opens next week; dates, price band announcedAt the higher end of the price band, the company is expected to raise Rs 1,513.6 crore via its initial shale sale. The promoter holds 100 p...
- Mega diabetes drug to be cheaper soonWith Novartis losing patent protection for Vildagliptin in December, the cost of therapy is expected to reduce by over 50%.
- Cipla to market Novartis, and J&J’s products, while Alkem partners Dong A of South KoreaAlkem is bringing in a fresh brand. Evogliptin has been approved in South Korea and the company is waiting for an approval from the USFDA a...
- Glenmark Pharma logs 24% jump in Q1 net profit; revenue up 18%Consolidated sales for the pharma major at Rs 1,943 crore, up 18 per cent, was largely in line with Rs 1,950 crore estimated by analysts at...
- Five diabetes drugs in top-10 selling list; overtakes anti-infective, antibiotic medsInsulin brand Human Mixtard, oral formulation Glycomet GP, insulin Lantus, oral formulations Galvus Met and Janumet are now in the top-sell...
- Now, cut treatment cost by 80 per cent with new anti-diabetes drugThe economic burden of diabetes is high in India as most patients pay out-of-pocket, and due to lack of medical reimbursement.
- New diabetes drug cuts cost by 80%A completely new drug in the 'gliptin' family has disrupted the anti-diabetes market by lowering the cost of therapy for patients by 80%.
- Drugmakers launch cut-price versions of type 2 diabetes medicineDozens of Indian drugmakers have launched cut-price versions of teneligliptin, a new generation medicine for type 2 diabetes patients.
- Japanese company loses patent bid for diabetes drugThe Kolkata Patent Office, on an opposition filed by domestic drug firm Lupin, refused the patent application on grounds that it was "obvio...
- Mankind pharma joins the anti-diabetic drug warIndia's anti-diabetic market is one of the fastest growing therapy segments, with a growth exceeding 25% at Rs 7638 crore, according to the...
- Glenmark to launch 10-12 new products in India, eyes 18-20 per cent growthGlenmark Pharmaceuticals proposes to launch 10-12 new products in the domestic market during the current financial year (2015-16) and hopes...
- Glenmark expecting USFDA nod for 4-6 products this fiscalGlenmark Pharmaceuticals is expecting approvals for four to six new products during the fiscal from the US Food and Drug Administration (US...
- New medicine could help diabetics save Rs 10,000 per yearA new anti-diabetes drug from the 'gliptin' family soon to be launched in India promises to lower treatment cost for patients by 55-60%.
Load More
